- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05078138
Impact of Erythropoietin on Hematological Adaptations and Physical Performance
September 19, 2023 updated by: United States Army Research Institute of Environmental Medicine
Negative hematological adaptations due to prolonged periods of strenuous physical activity may, in part, contribute to declines in physical performance during military operations.
Exogenous erythropoietin (EPO) is a potential intervention that may be used to maintain hemoglobin (hgb), hematocrit (Hct), and physical performance during periods of high physical activity.
The objective of the current study is to determine the ability of EPO to maintain hgb, Hct, and physical performance compared to baseline measures.
Additionally, EPO may result in non-hematological adaptations which increase mitochondria biogenesis and alter substrate oxidation.
As such, this study will also assess the influence of EPO on whole-body and skeletal muscle substrate oxidation.
Eight healthy physically active individuals will be recruited to participate in this longitudinal trial.
After exercise practice sessions, volunteers will complete baseline physical performance (time trial) and substrate oxidation testing.
Participants will then receive EPO injections 3 times per week for 4 weeks.
Diet and exercise will be controlled during the injection period.
Participants will undergo four weeks of an intense physical training exercise program.
Every seventh day during the injection period a safety blood sample, assessing hematocrit, will be drawn, and participants will complete a 5 km time trial to determine the time course of changes in physical performance can be detected.
After the 4 weeks of EPO injections volunteers will complete the same physical performance and substrate oxidation testing.
Substrate oxidation will be assessed during 90-min steady-state load carriage (30% body mass) exercise on a treadmill at 55 ± 5% of VO2peak.
6-6-[2H2] glucose tracer technique and indirect calorimetry will be used measure substrate oxidation.
Muscle biopsies will be performed to measure muscle glycogen, enzyme activity, and molecular markers of metabolism and inflammation before, and immediately and 3-hrs post exercise.
Multiple blood samples will be collected throughout the study to determine alterations in hemoglobin, hematocrit, and markers of substrate metabolism, and inflammation.
All study procedures will occur at USARIEM.
The primary risks associated with this study include those associated with EPO injection, exercise, blood draws, and muscle biopsies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Healthy physically active individuals will be recruited to participate in this longitudinal trial.
After baseline assessments of body composition, resting metabolic rate (RMR), VO2peak and exercise familiarization; volunteers will complete physical performance and substrate oxidation testing.
Physical performance will be assessed using time trial.
Substrate oxidation will be assessed by volunteers performing 90-min of steady-state load carriage (30% body mass) exercise on a treadmill at 55 ± 5% of their VO2peak.
6-6-[2H2] glucose will be used as a tracer to assess glucose turnover.
Indirect calorimetry will be used to determine carbohydrate and fat oxidation.
Muscle biopsies will be performed to measure muscle glycogen, enzyme activity, and molecular markers of substrate metabolism before, immediately after, and 3-hrs post exercise.
Multiple blood samples will be collected on substrate oxidation protocol days.
To minimize carry over effects of muscle biopsies on subsequent exercise performance, volunteers will not exercise for 3 days.
During the first two days of this period, volunteers will undergo carbon monoxide (CO) rebreathing to measure Hgb mass and blood volume.
Volunteers will then receive EPO injections 3 times a week for 4 weeks.
During the injection period all volunteers will have safety blood draws to assess Hct once a week.
Volunteers will also complete a physical performance test once a week to determine time course change in performance with EPO compared to baseline.
Exercise training will be controlled during the injection phase, consisting of a combination of endurance- and resistance-type exercise.
During the final week of the injection phase body composition, resting metabolic rate (RMR) and VO2peak will be reassessed.
At the end of the 4-week injection phase volunteers will complete a final physical performance test and substrate oxidation protocol, followed by two CO rebreathing tests on subsequent days.
All food and beverages (except water) will be provided to volunteers beginning at the pre injection physical performance and substrate oxidation through the duration of the study.
All data collection will occur at USARIEM.
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Natick, Massachusetts, United States, 01760
- US Army Research Institute of Environmental Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 39 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Men and women aged 18 - 39 years
- Weight stable (±5 lbs) for at least 2 months prior to the start of the study
- Body mass index (BMI) between 18.5-30 kg/m2
- Recreationally active (minimum 2-4 days per week aerobic and/or resistance exercise)
- Refrain from taking any NSAIDS (i.e., aspirin, Advil®, Aleve®, Naprosyn®, or any aspirin-containing product for 10 days before and at least 5 days AFTER each muscle biopsy. (*Tylenol® or acetaminophen is ok to use if needed for discomfort)
- Refrain from the use of alcohol and nicotine while on study diets
- Supervisor approval for federal civilian employees working within the US Army Natick Soldier Systems Center
Exclusion Criteria:
- Metabolic or cardiovascular abnormalities, gastrointestinal disorders (i.e., kidney disease, diabetes, cardiovascular disease, hypertension etc.)
- Personnel or family history of blood clots
- Disease or medication (i.e., diabetes medications, statins, corticosteroids, etc) that affects macronutrient utilization and/or the ability to participate in strenuous exercise
- Allergies or intolerance to foods (including but not limited to lactose intolerance/milk allergy), vegetarian practices, or medications (including, but not limited to, lidocaine or phenylalanine) to be utilized in the study
- History of inflammatory bowel disease
- History of seizures
- Anemia (HCT < 38) and Sickle Cell Anemia/Trait
- Abnormal PT/PTT test or problems with blood clotting
- Present condition of alcoholism, use of nutritional/sports supplements, anabolic steroids, or other substance abuse issues
- History of malignancy
- Use of oral contraceptives or hormone replacement therapy due to increased risk of clotting
- Musculoskeletal injuries that compromise the ability to exercise
- Blood donation within 8 weeks of beginning the study
- Are unwilling or unable to eat study diets and foods provided and/or follow exercise prescriptions
- Pregnancy, post-partum status, or breastfeeding
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exogenous Erythropoietin
Recombinant human Erythropoietin subcutaneous injection of 50 IU/kg body mass 3 times per week for 4 week
|
Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of Hemoglobin
Time Frame: 4 weeks
|
Determine the effects of EPO on hemoglobin concentration compared to baseline during 4 weeks of overtraining.
|
4 weeks
|
Time to complete 5 km time trial
Time Frame: 4 weeks
|
Determine the time course change in time to complete a 5 km treadmill run with EPO compared to baseline.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Carbohydrate and Fat Oxidation
Time Frame: 4 weeks
|
Assess the influence of EPO non-hematological adaptation (carbohydrate and fat oxidation rates and skeletal muscle substrate oxidation and glucose turnover rates) following 4 weeks of overtraining compared to baseline.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2021
Primary Completion (Actual)
April 1, 2023
Study Completion (Actual)
April 1, 2023
Study Registration Dates
First Submitted
August 6, 2021
First Submitted That Met QC Criteria
October 13, 2021
First Posted (Actual)
October 14, 2021
Study Record Updates
Last Update Posted (Actual)
September 21, 2023
Last Update Submitted That Met QC Criteria
September 19, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-01H
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Physical Performance
-
Atılım UniversityNot yet recruitingCognitive Performance | Physical PerformanceTurkey
-
PepsiCo Global R&DCompletedSleep | Cognitive Performance | Balance | Physical PerformanceAustralia
-
West Virginia UniversityCompletedPhysical PerformanceUnited States
-
Bruno FigueiraVytautas Magnus UniversityCompletedPhysical PerformanceLithuania
-
Eastern Mediterranean UniversityCompletedPhysical PerformanceCyprus
-
University of ThessalyUnknown
-
Skidmore CollegeCompletedPhysical Performance
-
Eastern Mediterranean UniversityCompleted
Clinical Trials on Epoetin Alfa
-
Hospital de Clinicas de Porto AlegreOswaldo Cruz Foundation; Rio Grande do Sul State Health Department - SES/RSCompletedComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis
-
MegalabsAzidus LaboratoriesNot yet recruitingAnemia of Chronic Kidney DiseaseUruguay
-
M.D. Anderson Cancer CenterCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech, Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedKidney Diseases | Anemia
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedBlood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Mammaplasty | Cardiovascular Surgical Procedures | Blood Transfusion, Autologous
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.Terminated
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Products, L.P.CompletedCritical Illness | Anemia